{"id":5066,"date":"2024-10-11T17:08:11","date_gmt":"2024-10-11T09:08:11","guid":{"rendered":"https:\/\/flcube.com\/?p=5066"},"modified":"2024-10-13T17:02:50","modified_gmt":"2024-10-13T09:02:50","slug":"eli-lilly-expands-collaboration-with-keybioscience-to-develop-obesity-treatments-using-dacra-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=5066","title":{"rendered":"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform"},"content":{"rendered":"\n

Eli Lilly and Company (NYSE: LLY<\/a>) has announced an extension of its collaboration with KeyBioscience AG, a subsidiary of Danish biotech Nordic Bioscience, to advance the development of Dual Amylin Calcitonin Receptor Agonists (DACRA). This new class of potential treatments targets obesity and related disorders, marking a significant step in the journey to combat metabolic conditions.<\/p>\n\n\n\n

Under the expanded agreement, Lilly will secure worldwide rights to develop and commercialize DACRA molecules, including a new molecule designed to enter Phase II studies in patients with obesity and osteoarthritis (OA) later this year. KeyBioscience will be at the helm of this study, which is set to enroll 600 participants with dual primary endpoints focused on body weight and the alleviation of OA pain.<\/p>\n\n\n\n

The terms of the extended agreement outline an initial payment to KeyBioscience, with potential downstream considerations reaching up to USD 1.4 billion, contingent upon the achievement of specific development, regulatory, and commercial milestones. Additionally, KeyBioscience stands to receive tiered royalties on net sales, ranging from mid-single digits to low double digits.<\/p>\n\n\n\n

This strategic move by Lilly underscores the pharmaceutical giant’s commitment to innovating in the realm of metabolic disorder treatments. The DACRA platform’s potential to improve insulin sensitivity, suppress food intake, and enhance blood glucose control positions it as a promising avenue for treating type 2 diabetes and obesity.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience…<\/p>\n","protected":false},"author":1,"featured_media":5067,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[199,911,86],"class_list":["post-5066","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-eli-lilly","tag-nyse-lly","tag-obesity"],"yoast_head":"\nEli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience AG, a subsidiary of Danish biotech Nordic Bioscience, to advance the development of Dual Amylin Calcitonin Receptor Agonists (DACRA). This new class of potential treatments targets obesity and related disorders, marking a significant step in the journey to combat metabolic conditions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=5066\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=5066\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-11T09:08:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-13T09:02:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d6102d5642227cbacf264a7f168551bc.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"427\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5066#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5066\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform\",\"datePublished\":\"2024-10-11T09:08:11+00:00\",\"dateModified\":\"2024-10-13T09:02:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5066\"},\"wordCount\":235,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5066#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/d6102d5642227cbacf264a7f168551bc.jpeg\",\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Obesity\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5066#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5066\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=5066\",\"name\":\"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5066#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5066#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/d6102d5642227cbacf264a7f168551bc.jpeg\",\"datePublished\":\"2024-10-11T09:08:11+00:00\",\"dateModified\":\"2024-10-13T09:02:50+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience AG, a subsidiary of Danish biotech Nordic Bioscience, to advance the development of Dual Amylin Calcitonin Receptor Agonists (DACRA). This new class of potential treatments targets obesity and related disorders, marking a significant step in the journey to combat metabolic conditions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5066#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5066\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5066#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/d6102d5642227cbacf264a7f168551bc.jpeg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/d6102d5642227cbacf264a7f168551bc.jpeg\",\"width\":640,\"height\":427,\"caption\":\"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5066#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform - Insight, China's Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience AG, a subsidiary of Danish biotech Nordic Bioscience, to advance the development of Dual Amylin Calcitonin Receptor Agonists (DACRA). This new class of potential treatments targets obesity and related disorders, marking a significant step in the journey to combat metabolic conditions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=5066","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=5066","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-10-11T09:08:11+00:00","article_modified_time":"2024-10-13T09:02:50+00:00","og_image":[{"width":640,"height":427,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d6102d5642227cbacf264a7f168551bc.jpeg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=5066#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=5066"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform","datePublished":"2024-10-11T09:08:11+00:00","dateModified":"2024-10-13T09:02:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=5066"},"wordCount":235,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=5066#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d6102d5642227cbacf264a7f168551bc.jpeg","keywords":["Eli Lilly","NYSE: LLY","Obesity"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=5066#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=5066","url":"https:\/\/flcube.com\/?p=5066","name":"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=5066#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=5066#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d6102d5642227cbacf264a7f168551bc.jpeg","datePublished":"2024-10-11T09:08:11+00:00","dateModified":"2024-10-13T09:02:50+00:00","description":"Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience AG, a subsidiary of Danish biotech Nordic Bioscience, to advance the development of Dual Amylin Calcitonin Receptor Agonists (DACRA). This new class of potential treatments targets obesity and related disorders, marking a significant step in the journey to combat metabolic conditions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=5066#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=5066"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=5066#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d6102d5642227cbacf264a7f168551bc.jpeg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d6102d5642227cbacf264a7f168551bc.jpeg","width":640,"height":427,"caption":"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=5066#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/d6102d5642227cbacf264a7f168551bc.jpeg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5066"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5066\/revisions"}],"predecessor-version":[{"id":5594,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5066\/revisions\/5594"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/5067"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}